Skip to content
10-Q

Quarterly Report

ImmunityBio, Inc. IBRX

0001326110-26-000059

← back to feed
Filed
May 7, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 5, 2026 1.05B sh
Shares Diluted Q1 2026 · Mar 31, 2026 1.03B sh
Shares Diluted Q1 2026 · Mar 31, 2025 853.16M sh
Capex Q1 2026 · Mar 31, 2026 $1.78M
Capex Q1 2026 · Mar 31, 2025 $1.12M
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$75.36M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$85.91M
Short Term Debt Q1 2026 · Mar 31, 2026 $884K
Short Term Debt Q1 2026 · Dec 31, 2025 $1.75M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $205.19M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $88.33M
Cash And Equivalents Q1 2026 · Mar 31, 2025 $60.66M
Stockholders Equity Q1 2026 · Mar 31, 2026 −$870.01M
Stockholders Equity Q1 2026 · Dec 31, 2025 −$500.47M
Current Liabilities Q1 2026 · Mar 31, 2026 $67.95M
Current Liabilities Q1 2026 · Dec 31, 2025 $61.75M
Total Liabilities Q1 2026 · Mar 31, 2026 $1.52B
Total Liabilities Q1 2026 · Dec 31, 2025 $1B
Current Assets Q1 2026 · Mar 31, 2026 $452.95M
Current Assets Q1 2026 · Dec 31, 2025 $314.88M
Total Assets Q1 2026 · Mar 31, 2026 $646.64M
Total Assets Q1 2026 · Dec 31, 2025 $501.9M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.62
Eps Diluted Q1 2026 · Mar 31, 2025 −$0.15
Eps Basic Q1 2026 · Mar 31, 2026 −$0.62
Eps Basic Q1 2026 · Mar 31, 2025 −$0.15
Net Income Q1 2026 · Mar 31, 2026 −$632.78M
Net Income Q1 2026 · Mar 31, 2025 −$129.65M
Operating Income Q1 2026 · Mar 31, 2026 −$69.79M
Operating Income Q1 2026 · Mar 31, 2025 −$64.43M
Cost Of Revenue Q1 2026 · Mar 31, 2026 $238K
Cost Of Revenue Q1 2026 · Mar 31, 2025 $58K
Revenue Q1 2026 · Mar 31, 2026 $44.21M
Revenue Q1 2026 · Mar 31, 2025 $16.52M